DKK1 and gastroesophageal junction adenocarcinoma: The DKK1 RNAscope laboratory developed test is currently being applied as part of a phase 2 clinical study of DKN-01 in combination with tislelizumab to prospectively identify second-line G/GEJ adenocarcinoma patients with elevated tumoral expression, and as a retrospective analysis of first-line patients treated with DKN-01 in combination with tislelizumab and chemotherapy (NCT04363801).